Registered business · Amay · BE · Founded 2013 · Accounts through 2025 · Updated Jul 27, 2026
Public range today€110k - €290k
See what is holding the value back today, what this company could be worth in five years and which actions make the difference. The estimate is based on filed annual accounts.
Is this your company? Claim and manage this profile
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsThe historical valuation curve is public. Create a free account for the future five-year growth forecast, the insights behind it, and concrete action points that can increase this company’s value.
Free account · private workspace
Public filings are a starting point. Owner-confirmed accounts, net debt, leases and commercial context can refine the range for a sale, financing or transfer.
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
Register your interest privately. Upswitch reviews every request and keeps it queued until a safe, verified owner contact route is available.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Claim this companyOperating as a business in NACE sector 73.30, European Drug Development Consulting is registered in Amay, Belgium. The company was founded in 2013, incorporated as a Besloten Vennootschap.
European Drug Development Consulting is listed in Belgian Crossroads Bank for Enterprises (KBO) under registry number 0540806771 and VAT number BE0540806771. This profile consolidates KBO registry, official annual accounts into one indexable company dossier.
Companies in this NACE 73.30 band file annual accounts with NBB/CBSO.
Across the 2024-2025 window the gross-margin line has stayed broadly flat, moving from €318,409 to €319,886. EBITDA for 2025 comes in at €311,219. Because this line is gross margin from an abbreviated filing, not reported turnover, it is treated as public context rather than an automatic valuation base.
A public indicative value curve is available for European Drug Development Consulting, based on filed company accounts. A free account unlocks the five-year outlook and concrete actions to increase value.
The most recent annual filing covers 2025 (period end 2025-12-31).
This page is refreshed whenever new regulator-filed data for European Drug Development Consulting becomes available, consolidated into a single audit-grade view.
Public regulator-filed figures across 2 years.
Fiscal year | Gross margin | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Dec 2025 | €319,886 | €311,219 | €163,032 | €30,078 | - |
| 202431 Dec 2024 | €318,409 | €315,976 | €164,750 | €20,460 | - |
European Drug Development Consulting was founded in 2013 and is registered with Belgian Crossroads Bank for Enterprises (KBO), incorporated as a Besloten Vennootschap.
European Drug Development Consulting is registered under NACE 73.30. That places the business within the Belgian cluster for this activity.
According to the company registry, European Drug Development Consulting is based in Amay, BE.
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-12-31), publicly available via Belgian Crossroads Bank for Enterprises (KBO).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for European Drug Development Consulting may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
Indicative public valuation range based on financial year 2025. This historical record does not yet contain an immutable calculation snapshot, so no sector range is reconstructed after the fact. Not a transaction value, asking price or fairness opinion.
Public profiles for peers in the same industry and country. Click through to compare filings and indicative valuations.
